RxDoctor Payments Data

Pedro Villablanca Spinetto, MD

Cardiovascular Disease · Detroit, MINPI 1518254630

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (57.2%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Edwards Lifesciences accounts for 71.3% of it on its own, with 25 other manufacturers making up the rest. Among cardiovascular disease clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$620,364in general payments, 2019–2025

Across 914 payments — averaging $678.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$442K
  • Abiomed$81K
  • Medtronic$37K
  • Angiodynamics, Inc.$27K
  • Teleflex LLC$19K
  • Abbott$6K
  • plus $9K from 20 others
$223,905in research payments, 2019–2025

Across 14 payments — averaging $15,993 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Edwards Lifesciences$129K
  • Arrow International, Inc.$59K
  • Essential Medical, Inc.$36K

What the payments were for

  • Consulting fees$355,15557%
  • Speaking & faculty fees$138,62822%
  • Travel & lodging$97,88616%
  • Food & beverage$28,6955%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$620,364 in reported general payments places this provider in the 95th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$191,220
Medicare patients
194
Services billed
829

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban48$51,537
XareltoRivaroxaban14$11,596
ClopidogrelClopidogrel Bisulfate33$907
Metoprolol Succinate41$708
Atorvastatin Calcium29$494
Bumetanide12$469
Losartan Potassium21$232
Furosemide30$215
Spironolactone21$195
Rosuvastatin Calcium11$164
Warfarin Sodium24$154
Amlodipine Besylate25$126
Potassium Chloride11$113
Lisinopril12$105
Omeprazole12$90

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →